The power of real-world data in clinical development and post-market activities

Diversity Action Plans: regulatory requirements and clinical trial enrollment goals

Developing comprehensive strategies to assess abuse liability/potential of brain-penetrant compounds

Creating a comprehensive drug development plan

Providing regulatory support in China for a new compound

Achieving sponsor goals with efficient end-to-end solutions

Strategic considerations when planning an externally controlled single-arm trial

Why literature reviews should be a key part of your evidence-generation strategy

The power of RWD in clinical development and post-market activities

An overview of real-wold data (RWD) and real-world evidence (RWE) and its benefits in drug development and post-market activities with examples of how RWD/RWE supports a product's value throughout the development life cycle.

Regulatory strategy considerations for advanced therapies

Inflation Reduction Act (IRA): Assessing the implications of Medicare drug price negotiations for drug development sponsors

Digital transformation in market access

Digital transformation is a grand phase—it can cover technological innovation, data and processes and even global organizational change, yet it doesn't have to be a daunting prospect left to those loooknig for systemic change at a company level.

Assessing the implications of Medicare drug price negotiations for drug development sponsors